England’s health-research governance body
A high-profile trial examining puberty blockers for about 220 children aged 11‑16 is moving forward after a High Court judge rejects a last-minute challenge to delay the Pathways study. The court has found no realistic prospect of success for the bid, and recruitment is set to begin from August 1 under strict safeguards.